Efficacy and safety of Ayurvedic herbs in diarrhoea-predominant irritable bowel syndrome: A randomised controlled crossover trial

被引:27
|
作者
Lauche, Romy [1 ,2 ]
Kumar, Syal [1 ,3 ]
Hallmann, Julia [1 ]
Luedtke, Rainer [4 ]
Rampp, Thomas [1 ]
Dobos, Gustav [1 ]
Langhorst, Jost [1 ,5 ]
机构
[1] Univ Duisburg Essen, Fac Med, Kliniken Essen Mitte, Dept Internal & Integrat Med, Essen, Germany
[2] Univ Technol Sydney, Fac Hlth, Australian Res Ctr Complementary & Integrat Med A, Sydney, NSW 2007, Australia
[3] Kliniken Essen Mitte, Dept Tradit Indian Med Ayurveda, Essen, Germany
[4] Karl & Veronica Carstens Fdn, Essen, Germany
[5] Univ Duisburg Essen, Fac Med, Kliniken Essen Mitte, Dept Integrat Gastroenterol, Essen, Germany
关键词
Ayurveda; Diarrhoea; Herbal therapy; Irritable bowel syndrome; Randomised controlled trial; ALTERNATIVE MEDICINE USE; QUALITY-OF-LIFE; NATIONAL-SURVEY; DOUBLE-BLIND; COMPLEMENTARY; DISORDERS; DISEASE; VALIDATION; SEVERITY;
D O I
10.1016/j.ctim.2016.04.002
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objective: Herbal medicines have been used widely for the treatment of irritable bowel syndrome (IBS) patients. The aim of this study is to investigate efficacy and safety of an Ayurvedic herbal compound preparation made from: Murraya koenigii (curry), Punica granatum (pomegranate) and Curcuma longa (turmeric), compared to a placebo in patients with diarrhoea predominant IBS. Material and methods: This trial was conducted as a randomised placebo-controlled crossover trial with randomised sequence of verum and placebo for each patient. Verum and placebo were provided as ground powders and delivered in sealed containers. Patients and outcome assessors were blinded. Patients were advised to ingest the decoction twice daily for 4 weeks. The primary outcome measure was IBS symptom intensity; secondary outcomes included: quality of life, anxiety and depression, compliance and safety. Results: 32 IBS patients were included in the trial (19 females, mean age 50.3 +/- 11.9 years). Eleven people dropped out during the trial resulting in 37 complete verum and 35 complete placebo phases. No group differences were found between verum and placebo for IBS symptom intensity (difference 24.10; 95% CI: -17.12; 65.32, p = 0.26). The same was true for secondary outcomes. Compliance was satisfactory to good and the preparation appeared to be safe, but one third of the patients registered at least one minor adverse event that might be related to the study interventions. Conclusion: An Ayurvedic herbal preparation made from Murraya koenigii, Punica granatum and Curcuma longa appeared to be no more effective in improving diarrhoea predominant irritable bowel symptoms than placebo. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:171 / 177
页数:7
相关论文
共 50 条
  • [1] Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial
    Trifan, Anca
    Burta, Ovidiu
    Tiuca, Nicoleta
    Petrisor, Diana Corina
    Lenghel, Augustin
    Santos, Javier
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2019, 7 (08) : 1093 - 1101
  • [2] Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial
    Leighton, Matthew P.
    Lam, Ching
    Mehta, Samir
    Spiller, Robin C.
    TRIALS, 2013, 14
  • [3] Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome
    Laterza, Lucrezia
    Ianiro, Gianluca
    Scoleri, Iolanda
    Landi, Rosario
    Bruno, Giovanni
    Scaldaferri, Franco
    Gaetani, Eleonora
    Campanale, Mariachiara
    Gasbarrini, Antonio
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (04) : 607 - 615
  • [4] Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial
    Matthew P Leighton
    Ching Lam
    Samir Mehta
    Robin C Spiller
    Trials, 14
  • [5] Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome
    Gillian M. Keating
    Drugs, 2017, 77 : 1009 - 1016
  • [6] Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial
    Aroniadis, Olga C.
    Brandt, Lawrence J.
    Oneto, Caterina
    Feuerstadt, Paul
    Sherman, Alex
    Wolkoff, Allan W.
    Kassam, Zain
    Sadovsky, Rotem Gura
    Elliott, Ryan J.
    Budree, Shrish
    Kim, Mimi
    Keller, Marla J.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (09): : 675 - 685
  • [7] Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome
    Whitehead, W. E.
    Duffy, K.
    Sharpe, J.
    Nabata, T.
    Bruce, M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (01) : 14 - 26
  • [8] Instability of the faecal microbiota in diarrhoea-predominant irritable bowel syndrome
    Durban, Ana
    Abellan, Juan J.
    Jimenez-Hernandez, Nuria
    Artacho, Alejandro
    Garrigues, Vicente
    Ortiz, Vicente
    Ponce, Julio
    Latorre, Amparo
    Moya, Andres
    FEMS MICROBIOLOGY ECOLOGY, 2013, 86 (03) : 581 - 589
  • [9] Long-term efficacy and safety of sacral neuromodulation for diarrhoea-predominant and mixed irritable bowel syndrome
    Fassov, J.
    Hoyer, K. L.
    Lundby, L.
    Laurberg, S.
    Scott, S. M.
    Krogh, K.
    TECHNIQUES IN COLOPROCTOLOGY, 2025, 29 (01)
  • [10] Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome
    Lacy, Brian E.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (08) : 817 - 830